短期内，亚盛医药业绩主要赖于耐立克的本土销售收入以及国际开发进展。多家券商给出了颇为乐观的业绩预测。其中国内 CML 患病存量约 20 万人，新适应症覆盖面增至原先 3-5 倍， 2025 年医保生效后放量速度或显著提升；美国三线 CML 市场规模约 ...

Kymera Therapeutics Inc. has published the characterization of KT-253, a novel compound designed to degrade the murine double minute 2 (MDM2) protein, offering a promising approach for cancers ...

癌症背后的分子机制一直是科学研究的热点。在癌症的众多驱动因素中，TP53基因被誉为“基因组的守护者”，是人类体内最重要的肿瘤抑制基因之一。然而，这位“守护者”也常常成为癌症发展的“叛徒”，数据显示，大约50%的癌症患者都携带TP53基因的突变。这些突 ...

生命科学Life science2025年1月6日，中国科学院遗传与发育生物学研究所郭伟翔研究组在Cell Press细胞出版社期刊Developmental Cell上发表了题为“Lactate shuttling links histone ...

Kymera Therapeutics, Inc., 500 North Beacon Street, Watertown, Massachusetts. *Corresponding Author: Yogesh K. Chutake, Kymera Therapeutics, Inc., 500 North Beacon ...

It is administered through oral route. The drug candidate is a new chemical entity. It acts by targeting MDM2-p53. It is a small-molecule mouse double minute 2 homolog (MDM2) inhibitor. The drug ...

Afterward, based on the state-value function, the algorithms via the Q-learning technique are exploited to estimate the controllability and observability probabilities along with obtaining the ...

INR:0411. hardik pandya age Hebo Pharmaceuticals passed the hearing of the Hong Kong Stock Exchange and 4 innovative drug candidates have entered the clinical s ...

Ascentage Pharma (6855.HK) is a global, integrated biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily in ...

A RT‒qPCR analysis of p53 mRNA in MGC-803 cells transduced with shNC or shNOLC1 lentivirus and treated with PBS or Cis (15 µM). B RT‒qPCR analysis of MDM2 mRNA in MGC-803 cells transduced with shNC or ...